Akari Therapeutics PLC (NASDAQ:AKTX) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Monday, September 11th.
Other equities analysts also recently issued research reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Akari Therapeutics PLC in a research note on Tuesday, July 4th. Zacks Investment Research raised shares of Akari Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Chardan Capital reissued a “neutral” rating and set a $2.50 price target (down previously from $6.00) on shares of Akari Therapeutics PLC in a research report on Friday, August 11th. Finally, Canaccord Genuity restated a “buy” rating and issued a $15.00 target price (down previously from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $8.00.
Akari Therapeutics PLC (AKTX) opened at 5.59 on Monday. The firm’s market capitalization is $65.83 million. The company’s 50-day moving average price is $4.17 and its 200 day moving average price is $7.23. Akari Therapeutics PLC has a 12 month low of $3.18 and a 12 month high of $22.20.
WARNING: This story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://stocknewstimes.com/2017/09/21/akari-therapeutics-plc-aktx-lifted-to-sell-at-valuengine.html.
A hedge fund recently bought a new stake in Akari Therapeutics PLC stock. Hikari Power Ltd purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.85% of the company’s stock.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.